In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta

Blood

Volumn 114, Issue 2, 2009, Pages 459-468

  Panaroni, Cristina ^a,b   Gioia, Roberta ^c   Lupi, Anna ^c   Besio, Roberta ^c   Goldstein, Steven A ^d   Kreider, Jaclynn ^d   Leikin, Sergey ^e   Vera, Juan Carlos ^e   Mertz, Edward L ^e   Perilli, Egon ^f   Baruffaldi, Fabio ^f   Villa, Isabella ^g   Farina, Aurora ^c   Casasco, Marco ^c   Cetta, Giuseppe ^c   Rossi, Antonio ^c   Frattini, Annalisa ^a,b   Marini, Joan C ^h   Vezzoni, Paolo ^a,b   Forlino, Antonella ^c  

^a CNR   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF MICHIGAN   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; ENHANCED GREEN FLUORESCENT PROTEIN; COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORTICAL BONE; EMBRYO; EXTRACELLULAR MATRIX; FEMALE; FETUS; HEMATOPOIETIC TISSUE; IN UTERO STEM CELL TRANSPLANTATION; LETHALITY; MALE; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PHENOTYPE; PRIORITY JOURNAL; RAMAN SPECTROMETRY; TRABECULAR BONE; AGING; ANIMAL; BONE MARROW TRANSPLANTATION; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DOMINANT GENE; DONOR; EXTRACELLULAR SPACE; FETAL RESEARCH; GENE TARGETING; GRAFT SURVIVAL; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; PREGNANCY; SURVIVAL RATE; TRANSGENIC MOUSE; UTERUS;

AGING; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; COLLAGEN; DISEASE MODELS, ANIMAL; EXTRACELLULAR SPACE; FEMALE; FETAL RESEARCH; GENE KNOCK-IN TECHNIQUES; GENES, DOMINANT; GRAFT SURVIVAL; MICE; MICE, TRANSGENIC; OSTEOGENESIS IMPERFECTA; PHENOTYPE; PREGNANCY; SPECTRUM ANALYSIS, RAMAN; SURVIVAL RATE; TISSUE DONORS; UTERUS;

EID: 67651091674     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-195859     Document Type: Article

References (51)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-74. (Pubitemid 27161245)
2. Byers PH, Cole GC. Osteogenesis imperfecta. In: Royce PM, Steinmann B, eds. Connective Tissue and its Heritable Disorders. 2nd Ed. New York, NY: Wiley-Liss; 2002:385-430.
3. Kuivaniemi H, Tromp G, Prockop DJ. Mutations in collagen genes: causes of rare and some common diseases in humans. FASEB J. 1991;5: 2052-2060. (Pubitemid 121000169)
4. Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tato L. Osteogenesis imperfecta: practical treatment guidelines. Paediatr Drugs. 2000;2:465-488.
5. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100.
6. Rauch F, Glorieux FH. Treatment of children with osteogenesis imperfecta. Curr Osteoporos Rep. 2006;4:159-164.
7. Millington-Ward S, McMahon HP, Farrar GJ. Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol Med. 2005;11: 299-305. (Pubitemid 40804794)
8. Chamberlain JR, Deyle DR, Schwarze U, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther. 2008;16:187-193.
9. Cabral WA, Marini JC. High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet. 2004;74:752-760.
10. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97:1227-1231.
11. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5: 309-313.
12. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002; 99:8932-8937.
13. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79:1607-1614. (Pubitemid 40847594)
14. Pereira RF, O'Hara MD, Laptev AV, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1998;95:1142-1147.
15. Li F, Wang X, Niyibizi C. Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation. Stem Cells. 2007;25:3183-3193. (Pubitemid 350294444)
16. Guillot PV, Abass O, Bassett JH, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood. 2008;111:1717-1725. (Pubitemid 351213464)
17. Wang X, Li F, Niyibizi C. Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: implications of cell therapy for skeletal diseases. Stem Cells. 2006;24:1869-1878. (Pubitemid 44474163)
18. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells. 2007;25:2896-2902.
19. Pihlajaniemi T, Dickson LA, Pope FM, et al. Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation. J Biol Chem. 1984;259:12941-12944. (Pubitemid 15223801)
20. Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC. Use of the Cre/lox recombination system to develop a nonlethal knock-in murine model for osteogenesis imperfecta with an α1(I) G349C substitution. Variability in phenotype in BrtlIV mice. J Biol Chem. 1999;274:37923-37931. (Pubitemid 30026860)
21. Engel J, Prockop DJ. The zipper-like folding of collagen triple helices and the effects of mutations that disrupt the zipper. Annu Rev Biophys Biophys Chem. 1991;20:137-152.
22. Ying QL, Wray J, Nichols J, et al. The ground state of embryonic stem cell self-renewal. Nature. 2008;453:519-523. (Pubitemid 351733324)
23. Chambers I, Smith A. Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene. 2004;23:7150-7160. (Pubitemid 39382149)
24. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol. 2002;12:432-438. (Pubitemid 35239952)
25. Choumerianou DM, Dimitriou H, Kalmanti M. Stem cells: promises versus limitations. Tissue Eng Part B Rev. 2008;14:53-60.
26. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147. (Pubitemid 29282067)
27. Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 1998;279:1528-1530. (Pubitemid 28217075)
28. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2:313-319.
29. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. Blood. 1999;94:2179-2191.
30. Peranteau WH, Hayashi S, Kim HB, Shaaban AF, Flake AW. In utero hematopoietic cell transplantation: what are the important questions? Fetal Diagn Ther. 2004;19:9-12. (Pubitemid 37500545)
31. Hayashi S, Peranteau WH, Shaaban AF, Flake AW. Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood. 2002; 100:804-812. (Pubitemid 34832605)
32. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997;407:313-319. (Pubitemid 27199450)
33. Dobson KR, Reading L, Haberey M, Marine X, Scutt A. Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int. 1999;65:411-413. (Pubitemid 29514082)
34. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood. 2004; 103:1662-1668. (Pubitemid 38268957)
35. Frattini A, Blair HC, Sacco MG, et al. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci U S A. 2005;102: 14629-14634. (Pubitemid 41457107)
36. Uveges TE, Collin-Osdoby P, Cabral WA, et al. Cellular mechanism of DECREASED Bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res. 2008;6:6.
37. Bilic-Curcic I, Kronenberg M, Jiang X, et al. Visualizing levels of osteoblast differentiation by a two-color promoter-GFP strategy: type I collagen- GFPcyan and osteocalcin-GFPtpz. Genesis. 2005;43:87-98. (Pubitemid 41598818)
38. Kucia M, Reca R, Jala VR, Dawn B, Ratajczak J, Ratajczak MZ. Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells. Leukemia. 2005;19:1118-1127. (Pubitemid 40945992)
39. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991;19: 4293.
40. Robey PG, Termine JD. Human bone cells in vitro. Calcif Tissue Int. 1985;37:453-460.
41. Forlino A, Tani C, Rossi A, et al. Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics. 2007;7:1877-1891. (Pubitemid 46911006)
42. Kozloff KM, Carden A, Bergwitz C, et al. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res. 2004;19:614-622. (Pubitemid 41071222)
43. Dominici M, Marino R, Rasini V, et al. Donor cell-derived osteopoiesis originates from a self-renewing stem cell with a limited regenerative contribution after transplantation. Blood. 2008; 111:4386-4391.
44. Baena E, Ortiz M, Martinez AC, de Alboran IM. c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21. Exp Hematol. 2007; 35:1333-1343. (Pubitemid 47302585)
45. Uveges TE, Bergwitz C, Kozloff KM, et al. Homozygosity for a dominant negative type I collagen mutation attenuates the type IV OI phenotype of the heterozygous Brtl mouse: insight into desease mechanism. Bone. 2005;36:S128-S129.
46. Kuznetsova NV, Forlino A, Cabral WA, Marini JC, Leikin S. Structure, stability and interactions of type I collagen with GLY349-CYS substitution in α1(I) chain in a murine osteogenesis imperfecta model. Matrix Biol. 2004;23:101-112. (Pubitemid 38891524)
47. Martin RB, Burr BB, Sharkey NA. Skeletal Tissue Mechanics. New York, NY: Springer; 1998.
48. Forlino A, Kuznetsova NV, Marini JC, Leikin S. Selective retention and degradation of molecules with a single mutant α1(I) chain in the Brtl IV mouse model of OI. Matrix Biol. 2007;26:604-614.
49. Prockop DJ. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 2007;82:241-243.
50. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25:646-654. (Pubitemid 46354223)
51. Mood A, Graybill F, Boes D. Introduction to the Theory of Statistics. 3rd ed. New York, NY: McGraw-Hill; 1974.